Progress Report
Study Rationale:
Dysfunctional mitochondria and oxidative stress are key drivers of neurodegeneration in Parkinson’s disease. Several proteins that regulate these processes likely underlie why certain brain and peripheral cells are especially vulnerable. Yet existing detection tools often perform unreliably in brain tissue and are not optimized for modern, high-plex imaging that measures many proteins at once. This gap limits our ability to map where these proteins act and how they contribute to disease. Our project will create rigorously validated, multiplex-ready antibodies, and we will openly share the protocols, validation workflows, and results to enable broad, reproducible use across the field.
Hypothesis:
Generating knockout-validated, fluorescently labeled antibodies to Parkinson’s disease-associated mitochondrial and oxidative-stress proteins will let researchers map these pathways, link them to specific cell types, and define how they change in the presence of Parkinson’s pathology across brain and peripheral tissues, revealing cell-type specific mechanisms and biomarkers that drive disease progression.
Study Design:
We will create panels of high-quality antibodies and fluorescently label them. Independent teams will validate performance stepwise: in knockout cell lines, in preclinical Parkinson’s models, and in human post-mortem brain and peripheral tissues (e.g., gut, skin, blood). We will test across routine fixations (FFPE, PFA, fresh-frozen), establish best-practice protocols, and assemble multiplex panels that co-stain cell types, organelles, and alpha-synuclein pathology. Cross-lab checks ensure reproducibility. All established protocols, and data will be released openly.
Impact on Diagnosis/Treatment of Parkinson’s disease:
These standardized reagents will enable consistent, high-resolution studies of mitochondrial and oxidative-stress pathways in Parkinson’s disease, accelerating discovery of disease mechanisms and tissue/blood biomarkers. These reagents will also provide robust pharmacodynamic readouts for therapy development and patient stratification, including peripheral targetengagement markers that track with brain pathology.
Next Steps for Development:
With validated panels, we will be able to scale to larger human cohorts and clinic-ready assays (PBMCs, skin, gut) to screen disease-related changes as biomarkers. We will then deploy these biomarkers in therapeutic studies to test whether candidate drugs engage targets and produce meaningful biological effects.